CD274 and non-small cell lung carcinoma: Moreover, another phase III trial is assessing the efficacy of the combination of lenvatinib plus pembrolizumab versus pembrolizumab alone in the first line in patients with advanced NSCLC, a PDL-1 greater than or equal to 1%, but who have been selected for RET positivity [58].